Biohaven pops the Alzheimer’s bubble
Troriluzole has failed in an Alzheimer’s trial, reminding the markets that this is par for the course in this disease.
Aducanumab tops 2021’s biggest potential launches
Blockbuster sales are predicted for several projects nearing approval, from Biogen, Argenx, Fibrogen and others.
Company Events
Go or no go? New Year approval decisions for the US regulators
Aurinia’s only project is due in front of the FDA, and outcomes are expected for Merck KGaA, Bayer and Merck & Co.
First-quarter catalysts for the smaller players
Important data releases are on the cards for Rhythm, Wave and Supernus, among others.
Key upcoming clinical catalysts for biotech
Early 2021 will see rare diseases dominate for biotech, with Sarepta revealing key data on its gene therapy play.
Interviews
Apellis takes the complement fight to Astrazeneca
The smaller company believes that its complement C3 inhibitor could make Soliris and Ultomiris redundant in PNH.
Kinaset takes a sledgehammer to an asthma conundrum
The nascent company hopes to prove that its inhaled pan-Jak is best in class.
Thermo Fisher and the new variant
Pinpointing new forms of the coronavirus could be vital, particularly if it mutates in response to vaccination, the company says.